Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation

被引:31
|
作者
Taha, Maie S. [1 ,2 ,3 ]
Padmakumar, Smrithi [1 ]
Singh, Amit [4 ]
Amiji, Mansoor M. [1 ]
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, 360 Huntington Ave, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Eye & Ear Infirmary, 243 Charles St, Boston, MA 02114 USA
[3] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt
[4] Puretech Hlth, 6 Tide St, Boston, MA 02210 USA
关键词
Nanomedicine; Clinical translation; Drug delivery; Challenges; Nanoparticles; Quality attributes; Quality-by-design (QbD); NANOPARTICLE SURFACE-CHARGE; DRUG-DELIVERY SYSTEMS; PROTEIN CORONA; POLYMERIC NANOPARTICLES; DESIGN APPROACH; HYBRID NANOPARTICLES; LIPID NANOPARTICLES; IN-VITRO; PHYSICOCHEMICAL PROPERTIES; INORGANIC NANOPARTICLES;
D O I
10.1007/s13346-020-00744-1
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
Nanomedicine is a rapidly emerging field with several breakthroughs in the therapeutic drug delivery application. The unique properties of the nanoscale delivery systems offer huge advantages to their payload such as solubilization, increased bioavailability, and improved pharmacokinetics with an overall goal of enhanced therapeutic index. Nanomedicine has the potential for integrating and enabling new therapeutic modalities. Several nanoparticle-based drug delivery systems have been granted approval for clinical use based on their outstanding clinical outcomes. Nanomedicine faces several challenges that hinder the realization of its full potential. In this review, we discuss the critical formulation- and biological-related quality features that significantly influence the performance of nanoparticulate systems in vivo. We also discuss the quality-by-design approach in the pharmaceutical manufacturing and its implementation in the nanomedicine. A deep understanding of these nanomedicine quality checkpoints and a systematic design that takes them into consideration will hopefully expedite the clinical translation process. Graphical abstract
引用
收藏
页码:766 / 790
页数:25
相关论文
共 50 条
  • [11] Critical Quality Attributes Challenge Biologics Development
    Haigney, Susan
    BIOPHARM INTERNATIONAL, 2017, 30 (04) : 33 - 34
  • [12] Using critical quality attributes in the development of biosimilars
    Bernat, Bryan
    TerWee, Julie
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [13] Defining Critical Quality Attributes for Monoclonal Antibody Therapeutic Products
    Rathore, Anurag S.
    Weiskopf, Andrew
    Reason, Andrew J.
    BIOPHARM INTERNATIONAL, 2014, 27 (07) : 34 - +
  • [14] Overcoming Barriers: Clinical Translation of siRNA Nanomedicines
    Tieu, Terence
    Wei, Yingkai
    Cifuentes-Rius, Anna
    Voelcker, Nicolas H.
    ADVANCED THERAPEUTICS, 2021, 4 (09)
  • [15] Clinical translation of nanomedicines: Challenges, opportunities, and keys
    Younis M.A.
    Tawfeek H.M.
    Abdellatif A.A.H.
    Abdel-Aleem J.A.
    Harashima H.
    Advanced Drug Delivery Reviews, 2022, 181
  • [16] Characterizing Critical Quality Attributes in Biopharmaceutical Drug Development
    Siew, Adeline
    BIOPHARM INTERNATIONAL, 2018, 31 (09) : 32 - 32
  • [17] Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
    Hua, Susan
    de Matos, Maria B. C.
    Metselaar, Josbert M.
    Storm, Gert
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [18] Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities
    Agrahari, Vibhuti
    Agrahari, Vivek
    DRUG DISCOVERY TODAY, 2018, 23 (05) : 974 - 991
  • [19] An update on microneedle in insulin delivery: Quality attributes, clinical status and challenges for clinical translation
    Alshammari, Mohammed Kanan
    Ghazwani, Jamila Ali
    Alsharari, Fahad Owaidh
    Alotaibi, Shahad Saleh
    Alotaibi, Rahaf Mohammad
    Alsayahani, Amwaj Abdullah
    Alosaimi, Rakan Bijad
    Alotaibi, Atheer Nasser
    Imran, Mohd
    Arshad, Mohammed Faiz
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2022, 75
  • [20] Clinical Translation of Self-Assembled Cancer Nanomedicines
    Mi, Peng
    Miyata, Kanjiro
    Kataoka, Kazunori
    Cabral, Horacio
    ADVANCED THERAPEUTICS, 2021, 4 (01)